

Cover Story
By Matthew Bin Han Ong
Summer of 2020 was supposed to be a brief period of respite between Wave 1 and Wave 2 of COVID-19, but out of sheer stubbornness, for reasons political, or both, SARS-CoV-2 didn't get the message.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
















